Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;333:808 (14 October), doi:10.1136/bmj.333.7572.808
| The first 150 words of the full text of this article appear below. |
EDITORTumour shrinkage by preoperative chemoradiotherapy is now an everyday reality, and pathological complete responses are not uncommon.1 A "new dilemma" is posed by the apparent complete disappearance of cancer on magnetic resonance imaging, and often clinically, after chemoradiotherapy. A delay of six to 10 weeks is usual before operatinga time perceived as a "window of opportunity," as regrowth in the irradiated area is believed inevitable.
This concept has been challenged by a series by Habr-Gama et al.2 Altogether 360 patients with T3 and T4 rectal cancer (or T2 when considered for abdominoperineal resection) were treated with preoperative chemoradiotherapy.3 Ninety nine patients (28%) classified as clinical complete responders at eight weeks after completion of chemoradiotherapy were managed by surveillance alone. Only 2% in this observation group have died of cancer in a follow-up extending for up to 10 years, whereas local recurrence occurred in just five patients, all amenable
R J Heald, surgical director1, Brian D P O'Neill, clinical oncology research fellow2, Brendan Moran, consultant surgeon2, Gina Brown, consultant radiologist3, Ara W Darzi, honorary consultant3, Andrew C Wotherspoon, consultant histopathologist3, David Cunningham, consultant medical oncologist3, Diana M Tait, consultant medical oncologist3
1 Pelican Cancer Foundation, Basingstoke RG24 9NA Completeresponse@pelicancancer.org, 2 Pelican Cancer Foundation, Basingstoke RG24 9NA, 3 Royal Marsden NHS Foundation Trust, London SW3 6JJ